Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

December 29, 2014

Primary Completion Date

August 25, 2023

Study Completion Date

December 29, 2028

Conditions
Non Hodgkin Lymphoma
Interventions
DRUG

acalabrutinib

DRUG

rituximab (IV)

DRUG

Lenalidomide

Trial Locations (32)

10021

Research Site, New York

10532

Research Site, Hawthorne

11042

Research Site, Lake Success

13210

Research Site, Syracuse

20132

Research Site, Milan

29615

Research Site, Greenville

33146

Research Site, Coral Gables FL

40138

Research Site, Bologna

40207

Research Site, Louisville

43210

Research Site, Columbus

48109

Research Site, Ann Arbor

53188

Research Site, Waukesha

60611

Research Site, Chicago

60612

Research Site, Chicago

60637

Research Site, Chicago

70112

Research Site, New Orleans

75235

Research Site, Dallas

76508

Research Site, Temple

77030

Research Site, Houston

78217

Research Site, San Antonio

84112

Research Site, Salt Lake City

85719

Research Site, Tucson

90146

Research Site, Palermo

90241

Research Site, Downey

90404

Research Site, Santa Monica

91010

Research Site, Duarte

92708

Research Site, Fountain Valley

99208

Research Site, Spokane

07960

Research Site, Morristown

t6G1Z2

Research Site, Edmonton

N6A 5W9

Research Site, London

M5G 2M9

Research Site, Toronto

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Acerta Pharma BV

INDUSTRY